Johanna Friedl-Naderer, Chief Commercial Officer at Dyne Therapeutics, Inc. (DYN), sold 143 shares at $12.12 ($2K) on 2025-03-13, disclosed to the SEC on 2025-03-13.
Scheduled sale ($2k) by Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| DYN | SELL | 2026-06-17 | $3K | — | Filing → |
| DYN | SELL | 2026-05-14 | $4K | — | Filing → |
| DYN | SELL | 2026-03-06 | $2K | — | Filing → |